Related Experiment Video
Updated: Apr 23, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
New targets for treating the underlying pathophysiology and nonmotor aspects of Parkinson's disease
Jonathan T Butler, Christopher Tolleson1
1Department of Neurology, Vanderbilt University, 1161 21st Avenue South, Medical Center North A- 0118, Nashville, Tennessee 37232, USA. jonathan.t.butler@vanderbilt.edu.
Abstract:
Parkinson's disease is a common neurodegenerative disease diagnosed by well established clinical motor symptoms. However, the disease also encompasses many nonmotor issues that can impact a myriad of processes such as cardiovascular status, gastrointestinal function, autonomic function, mood and sleep. These issues can be more debilitating and impactful on health status in part because of a lack of effective treatments. The pathophysiology of the disease process is under active investigation with postulated mechanisms involving both the central nervous system and the periphery. More in depth examination of the many nonmotor symptoms may aid in the discovery of the overarching pathological origin and progression of Parkinson's disease. Examining the disease process from the perspective of nonmotor symptoms may also provide additional target pathways and potential drug development options not considered previously.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Parkinson Disease ll: Pathophysiology
Parkinson Disease l: Introduction
Alzheimer's Disease: Treatment
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

